Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313 in tuberculosis

09-Sep-2013 - France

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio’s IMX313. The study will be performed in the UK and led by Prof. Helen McShane from the Jenner Institute at Oxford University.

Imaxio's proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of each vaccine in which it is used. IMX313 brings significant potential as a solution to develop vaccines and immunotherapies for major indications. The technology was designed in response to the challenge in increasing the effectiveness of some human and animal health candidates. It is currently used for the development of vaccine candidates indicated for influenza, Staphylococcus aureus infection, tuberculosis and malaria.

”Following a number of successes with IMX313 in preclinical trials, we are really pleased to have reached this milestone: the first administration of IMX313 in humans,” explains Dr. Fergal Hill, chief scientific officer of Imaxio. “We believe strongly that this will confirm fully that IMX313 is a real solution for developing more effective human vaccines and for addressing major infectious diseases.”

https://www.bionity.com/en/news/144873/imaxio-announces-the-first-human-clinical-trial-using-its-pro-immunogenic-technology-imx313-in-tuberculosis.html